ArticleMultiple sclerosis journal - experimental, translational and clinical
Factors associated with delays in multiple sclerosis disease-modifying therapy initiation.
Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In multiple sclerosis (MS), delays in initiation of disease-modifying therapy (DMT) are associated with worse clinical outcomes. Methods: This single-center retrospective chart review study included treatment-naive and previously treated people with MS (PwMS) initiated on DMT between 01 September 2021 and 01 September 2023. A generalized linear model was utilized to evaluate associations between start-up times (initial treatment decision to completion of first dose) and distance to the clinic, utilization of the center's infusion center and specialty pharmacy, insurance and educational status, route of administration, race/ethnicity, and household income. Results: A total of 116 PwMS were included (median age 41 [15-74] years; 87.9% female). Increased geographic distance from the MS center correlated with longer start-up times (>100 km: 76.5 [0-393] days vs. ≤100 km: 53.5 [2-524] days); Conclusions: This small retrospective study demonstrates an association between longer start-up times and greater geographic distance, private insurance status, and use of outside infusion centers and specialty pharmacies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.